Limits on use of health economic assessments for rare diseases

SID > Fuentes Documentales > Publicaciones Periódicas > Artículos de Revistas > Limits on use of health economic assessments for rare diseases

Resumen

Funding of expensive treatments for rare (orphan) diseases is contentious. These agents fare poorly on ‘efficiency’ or health economic measures, such as the quality-adjusted life years, because of high cost and frequently poor gains in quality of life and survival. We show that cost-effectiveness assessments are flawed, and have only a limited role to play in reimbursement decisions for orphan drugs and beyond.

Resumen realizado por los autores recogido de la publicación

Publicación

Reino Unido:
QJM: Monthly Journal Of The Association Of Physicians,
2014

ISBN

1460-2393

Descripción física

241-245

Serie

Quizás te interese:

Recibe más documentos en tu email

No te pierdas todas nuestras actualizaciones